Foguth Wealth Management LLC. Acquires Shares of 2,078 Johnson & Johnson (NYSE:JNJ)

Foguth Wealth Management LLC. purchased a new position in Johnson & Johnson (NYSE:JNJ) in the first quarter, Holdings Channel reports. The fund purchased 2,078 shares of the company’s stock, valued at approximately $329,000.

A number of other hedge funds have also made changes to their positions in the stock. 4J Wealth Management LLC lifted its position in shares of Johnson & Johnson by 2.2% in the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after purchasing an additional 62 shares in the last quarter. My Personal CFO LLC lifted its position in shares of Johnson & Johnson by 1.4% in the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock worth $713,000 after purchasing an additional 62 shares in the last quarter. Eagle Strategies LLC lifted its position in shares of Johnson & Johnson by 1.8% in the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock worth $563,000 after purchasing an additional 63 shares in the last quarter. Clearview Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 1.5% in the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after purchasing an additional 64 shares in the last quarter. Finally, Brookmont Capital Management lifted its position in shares of Johnson & Johnson by 0.4% in the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock worth $2,328,000 after purchasing an additional 64 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the topic of a number of research reports. The Goldman Sachs Group initiated coverage on Johnson & Johnson in a report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price objective for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 20th. Morgan Stanley dropped their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Monday, June 17th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Trading Up 0.2 %

Shares of Johnson & Johnson stock opened at $146.16 on Monday. The company’s fifty day simple moving average is $148.14 and its 200-day simple moving average is $154.05. The company has a market cap of $351.76 billion, a price-to-earnings ratio of 9.11, a PEG ratio of 2.43 and a beta of 0.53. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the company posted $2.68 earnings per share. As a group, sell-side analysts expect that Johnson & Johnson will post 10.62 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.39%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.